Could a blood vessel drug boost brain recovery after a hemorrhage?

NCT ID NCT07144956

Not yet recruiting Disease control Sponsor: Centre Hospitalier St Anne Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding cilostazol, a drug that improves blood flow, to standard nimodipine treatment helps people recover better after a brain aneurysm rupture. Researchers will enroll 630 adults in France within 96 hours of the bleed and follow them for 6 months. The goal is to see if the combination reduces disability and improves daily function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cilostazol (Pletal®) 100 mg tablets
What this could lead to: If it works, this could point toward a better recovery for people who survive a brain aneurysm rupture, reducing long-term disability.
What could go wrong: This is a phase 3 trial, but it's still early to know if adding cilostazol truly helps. The study is limited to France, and results may not apply to everyone. There is also a risk of side effects from the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEURYSMAL SUBARACHNOID HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEURYSMAL SUBARACHNOID HEMORRHAGE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.